These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 32638458)
1. Pathological aspects of mucinous cholangiocarcinoma: A single-center experience and systematic review. Laohawetwanit T; Klaikaew N Pathol Int; 2020 Sep; 70(9):661-670. PubMed ID: 32638458 [TBL] [Abstract][Full Text] [Related]
2. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology. Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845 [TBL] [Abstract][Full Text] [Related]
3. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma. Sasaki M; Sato Y; Nakanuma Y Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289 [TBL] [Abstract][Full Text] [Related]
4. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Sasaki M; Sato Y; Nakanuma Y Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959 [TBL] [Abstract][Full Text] [Related]
5. Intraductal papillary mucininous neoplasm of the bile ducts: multimodality assessment with pathologic correlation. Takanami K; Yamada T; Tsuda M; Takase K; Ishida K; Nakamura Y; Kanno A; Shimosegawa T; Unno M; Takahashi S Abdom Imaging; 2011 Aug; 36(4):447-56. PubMed ID: 20959978 [TBL] [Abstract][Full Text] [Related]
6. Cytologic features of fibrolamellar carcinoma with mucin production: a rare variant of combined hepatocellular-cholangiocarcinoma. Rosa M; Mohammadi A Diagn Cytopathol; 2014 May; 42(5):431-5. PubMed ID: 23008149 [TBL] [Abstract][Full Text] [Related]
7. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Sasaki M; Sato Y; Nakanuma Y Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197 [TBL] [Abstract][Full Text] [Related]
8. A case of mucinous cholangiocarcinoma showing features of hepatocellular carcinoma. Kai K; Ide Y; Miyoshi A; Masuda M; Ide T; Kitahara K; Irie H; Nakajima J; Noshiro H; Tokunaga O Pathol Int; 2013 Aug; 63(8):419-21. PubMed ID: 23957918 [No Abstract] [Full Text] [Related]
9. Mucinous intrahepatic cholangiocarcinoma: a distinct variant. Chi Z; Bhalla A; Saeed O; Cheng L; Curless K; Wang HL; Patil DT; Lin J Hum Pathol; 2018 Aug; 78():131-137. PubMed ID: 29698701 [TBL] [Abstract][Full Text] [Related]
10. Subcentimetric Incidental Intrahepatic Cholangiocarcinoma in an Explant Liver: Diagnostic Difficulty of a Rare Entity. Mitra S; Geethanjali G; Rathi S; Behera A; Das A Int J Surg Pathol; 2018 Dec; 26(8):739-744. PubMed ID: 29742944 [TBL] [Abstract][Full Text] [Related]
11. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
13. [Intraductal papillary mucinous cholangiocarcinoma]. Han JK; Kim SH; Kim SJ Korean J Hepatol; 2007 Jun; 13(2):243-7. PubMed ID: 17585199 [No Abstract] [Full Text] [Related]
14. Combined hepatocellular-cholangiocarcinoma. Cytologic findings in four cases. Dusenbery D Acta Cytol; 1997; 41(3):903-9. PubMed ID: 9167724 [TBL] [Abstract][Full Text] [Related]
15. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764 [TBL] [Abstract][Full Text] [Related]
16. Mucin-hypersecreting bile duct tumor characterized by a striking homology with an intraductal papillary mucinous tumor (IPMT) of the pancreas. Kim HJ; Kim MH; Lee SK; Yoo KS; Park ET; Lim BC; Park HJ; Myung SJ; Seo DW; Min YI Endoscopy; 2000 May; 32(5):389-93. PubMed ID: 10817178 [TBL] [Abstract][Full Text] [Related]
17. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma. Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308 [TBL] [Abstract][Full Text] [Related]
18. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas. Patil PA; Taddei T; Jain D; Zhang X Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854 [TBL] [Abstract][Full Text] [Related]
20. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas. Sasaki M; Sato Y; Nakanuma Y Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]